Euroscreen S.a.

Applied Research Systems Ars Holding N.v.

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Humanitas Mirasole S.p.a.

Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Farma Development S.r.l.

Université D'angers

Humanitas University

Alberto Mantovani

Marc Parmentier

Gilbert Vassart

Michel Detheux

David Communi

Isabelle Migeotte

Marisa Vulcano

Silvano Sozzani

Stephane Brezillon

Jean-Denis Franssen

Cecile Loison

Jean-Francois Mirjolet

Valeria Wittamer

Emmanuel Le Poul

Marta Muzio

Frederic Ooms

Emmanuel Lepoul

Francesco Colotta

Barbara Bottazzi

Valerie Wittamer

Jean-Denis Franseen

Jean-François Mirjolet

Angelo Guglielmotti

Pascale Jeannin

Martino Introna

Marco Rusnati

Marco Presta

Stéphane Brézillon

Frédéric Ooms

Antonio Inforzato

J F Mirjolet

Valérie Wittamer

Yves Delneste

Emmanuel LePoul

Giuseppe Peri

Annunciata Vecchi

Irene Cetin

Andrea Doni

Cecilia Garlanda

Tamara Gulic

Ilaria Laface

Fabio Pasqualini

The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

Anti-human migration stimulating factor (MSF) and uses thereof

The present invention relates to a diagnostic test for inflammatory endothelial dysfunctions in pregnant women. Particularly, the present invention relates to a method of diagnosing or evaluating the risk of contracting an inflammatory endothelial dysfunction of the maternal compartment comprising the following steps: a) detecting the plasma levels of long pentraxin PTX3 in blood samples taken from a pregnant woman; b) comparing the PTX3 plasma level data, obtained according to step a), with statistically significant PTX3 plasma level data of normal pregnant population.

Diagnostic test for inflammatory endothelial dysfunctions in pregnancies

The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Methods of making an antibody that binds a chemerin polypeptide

Nucleic acids encoding ChemerinR ligands

Pharmaceutical compositions are described containing a long pentraxin PTX3, particularly human PTX3, for the therapy of infectious and inflammatory or tumor diseases; expression vectors containing cDNA coding for PTX3; recombinant host cells transfected with such vectors; a method for producing substantial amounts of PTX3 involving the culturing of such cells, and the use of said vectors in the gene therapy of tumors.

Pharmaceutical compositions containing the long pentraxin PTX3

Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.

Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination

Monoclonal antibodies that bind Chemerin polypeptide

The use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives is described for the preparation of medicament which inhibits the biological activity of the growth factor FGF-2, useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.

Use of the long pentraxin PTX3 for the treatment of diseases caused by an altered activation of the growth factor FGF-2

Methods of identifying modulators of ChemerinR polypeptides

Compositions comprising a ligand of Chemerin R

The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screeing assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Functional antibodies that specifically bind to the Chemerin receptor

Antibody that specifically binds to Chemerin receptor ligand precursor

Isolated ligand of ChemerinR

Methods of identifying modulators of ligand binding to ChemerinR polypeptides

The PTX3 gene or equivalent PTX3 activity is required for female fertility. Manipulation of PTX3 activity will regulate female fertility. The effects of female sterility may be ameliorated, reproductive ability may be increased or decreased as desired, female fertility may be enhanced, or combinations thereof. The need for therapies that affect female fertility is thereby addressed.

Compositions and methods for treating female fertility

Growing community of inventors

Milan, Italy

Alberto Mantovani